Peoples Financial Services CORP. increased its holdings in AbbVie Inc (NYSE:ABBV) by 1.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 23,137 shares of the company’s stock after buying an additional 282 shares during the period. Peoples Financial Services CORP.’s holdings in AbbVie were worth $1,752,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also bought and sold shares of ABBV. Nuveen Asset Management LLC boosted its holdings in shares of AbbVie by 1,715.8% in the 2nd quarter. Nuveen Asset Management LLC now owns 9,593,845 shares of the company’s stock valued at $697,664,000 after buying an additional 9,065,487 shares during the period. FMR LLC boosted its holdings in shares of AbbVie by 56.5% in the 1st quarter. FMR LLC now owns 13,200,141 shares of the company’s stock valued at $1,063,799,000 after buying an additional 4,765,946 shares during the period. BlackRock Inc. boosted its holdings in shares of AbbVie by 3.3% in the 2nd quarter. BlackRock Inc. now owns 98,295,272 shares of the company’s stock valued at $7,148,030,000 after buying an additional 3,100,309 shares during the period. Putnam Investments LLC boosted its holdings in shares of AbbVie by 433.3% in the 2nd quarter. Putnam Investments LLC now owns 3,634,868 shares of the company’s stock valued at $264,327,000 after buying an additional 2,953,331 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of AbbVie by 81.6% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,176,070 shares of the company’s stock valued at $376,404,000 after buying an additional 2,326,510 shares during the period. 68.24% of the stock is owned by institutional investors and hedge funds.
In related news, SVP Nicholas Donoghoe purchased 7,525 shares of the company’s stock in a transaction on Thursday, August 29th. The shares were bought at an average cost of $66.19 per share, for a total transaction of $498,079.75. Following the transaction, the senior vice president now owns 13,090 shares of the company’s stock, valued at $866,427.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roxanne S. Austin purchased 10,000 shares of the company’s stock in a transaction on Tuesday, July 30th. The shares were bought at an average price of $66.35 per share, for a total transaction of $663,500.00. Following the completion of the transaction, the director now directly owns 62,114 shares in the company, valued at approximately $4,121,263.90. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 183,077 shares of company stock worth $10,705,751. 0.08% of the stock is currently owned by insiders.
ABBV has been the subject of several research reports. ValuEngine raised shares of AbbVie from a “strong sell” rating to a “sell” rating in a report on Monday, September 30th. Wolfe Research raised shares of AbbVie from an “underperform” rating to a “peer perform” rating in a report on Thursday, June 27th. TheStreet lowered shares of AbbVie from a “b-” rating to a “c” rating in a report on Monday, August 26th. Leerink Swann raised shares of AbbVie to a “buy” rating in a report on Tuesday, July 2nd. Finally, Cowen set a $90.00 price target on shares of AbbVie and gave the company a “buy” rating in a report on Tuesday, September 24th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $89.97.
NYSE:ABBV traded up $0.24 during mid-day trading on Wednesday, hitting $74.74. The stock had a trading volume of 5,576,437 shares, compared to its average volume of 7,693,439. The stock has a market capitalization of $108.86 billion, a price-to-earnings ratio of 9.45, a P/E/G ratio of 1.50 and a beta of 0.99. The company has a 50 day simple moving average of $71.02 and a 200-day simple moving average of $73.76. AbbVie Inc has a 52 week low of $62.66 and a 52 week high of $94.98.
AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 26th. The company reported $2.26 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.21 by $0.05. The firm had revenue of $8.26 billion for the quarter, compared to the consensus estimate of $8.09 billion. AbbVie had a net margin of 12.62% and a negative return on equity of 182.70%. AbbVie’s quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the firm posted $2.00 EPS. Equities research analysts anticipate that AbbVie Inc will post 8.93 EPS for the current year.
The company also recently disclosed a — dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be given a $1.07 dividend. The ex-dividend date of this dividend is Friday, October 11th. This represents a yield of 6.4%. AbbVie’s dividend payout ratio is presently 54.11%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Article: How do candlesticks reflect price movement?
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.